摘要
目的分析复旦大学附属中山医院厦门医院(以下简称“本院”)住院患者2019—2021年口服降血脂药的应用情况及发展趋势,评价用药合理性,为临床合理用药提供参考。方法从医院信息管理系统(HIS)选取本院2019—2021年住院药房降血脂药物的使用数据,获取该类药物名称、规格、年出库总量与年销售总金额等。采用世界卫生组织(WHO)推荐的成人限定日剂量(DDD)、用药频度(DDDS)、日均费用(DDC)等进行统计分析,利用排序比(B/A)对药物使用的同步性进行比较。结果2019—2021年本院住院患者口服降血脂药用药金额年均增长率为8.19%,销售额相对平稳,呈逐年上升趋势。其中他汀类占主导,销售额连续3年最高,占比最多;其次为贝特类。DDDS排名中阿托伐他汀钙片连续3年排名第1位,非诺贝特胶囊逐年上升,且3年连续排名第2位,其他降血脂药DDDS相对稳定,略微波动。辛伐他汀片DDC值最高,非诺贝特胶囊DDC值排序三年均靠后。2019—2021年绝大部分降血脂药的B/A值接近于1,同步性较好。结论2019—2021年本院住院患者口服降血脂药使用情况较为合理,选用符合规范。药品种类相对稳定,用药情况符合规范要求。
Objective To analyze the application situation and development trend of oral hypolipidemic drugs in Zhongshan Hospital,Fudan University(Xiamen Branch)(hereinafter referred to as"our hospital")from 2019 to 2021,evaluate the rationality of drug use,and provide reference for clinical rational drug use.Methods The usage data of hypolipidemic drugs in inpatient pharmacy of our hospital from 2019 to 2021 were selected from the hospital information management system(HIS),and the names,specifications,annual total amount of discharged drugs and annual total sales amount of such drugs were obtained.The adult defined daily dose(DDD),frequency of drug daily dose(DDDS)and drug daily cost(DDC)recommended by the World Health Organization(WHO)were statistically analyzed,and the synchronization of drug use was compared by ranking ratio(B/A).Results The average annual growth rate of drug consumption of oral hypolipidemic drugs in inpatient of our hospital from 2019 to 2021 was 8.19%,and the sales volume was relatively stable,showing an upward trend year by year.In them,the use of Statins was dominant,with the highest sales amount for three consecutive years,accounting for the largest proportion,followed by Bette class.In the DDDS ranking,Atorvastatin calcium tablets ranked first for three consecutive years,Fenofibrate capsules increased year by year,and ranked second for three consecutive years,while DDDS of other hypolipidemic drugs was relatively stable and fluctuated slightly.The DDC value of Simvastatin tablets was the highest,while the DDC value of Fenofibrate capsules was lower in three years.From 2019 to 2021,the B/A values of the vast majority of hypolipidemic drugs were close to 1,with a relatively good synchronization rate.Conclusion The use of oral hypolipidemic drugs for inpatients in our hospital from 2019 to 2021 is reasonable,and the selection is in line with the specifications.The types of drugs are relatively stable,and the use of drugs meets the requirements of the specification.
作者
李静
陈少壮
范彩云
陈斌霞
陈琪琪
顾芙蓉
刘晓鹭
洪小玲
王永胜
沈赟
LI Jing;CHEN Shaozhuang;FAN Caiyun;CHEN Binxia;CHEN Qiqi;GU Furong;LIUXiaolu;HONG Xiaoling;WANG Yongsheng;SHEN Yun(Department of Pharmacy,Zhongshan Hospital,Fudan University(Xiamen Branch),Fujian,Xiamen 361015,China;Department of Pharmacy,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处
《中国医药科学》
2024年第12期95-99,174,共6页
China Medicine And Pharmacy
基金
厦门市医工结合指导性项目(3502Z20214ZD2176)。
关键词
降血脂药
用药频度
用药分析
用药金额
阿托伐他汀钙片
Hypolipidemic drugs
Frequency of drug daily dose
Drug use analysis
Amount of drug consumption
Atorvastatin calcium tablets
